Abstract
Thirty-two consecutive patients with pretreated germinal testis cancer received 3 to 4 inductions of cisplatin and etoposide therapy (PE). Patients not pretreated, or only partially pretreated with bleomycin (B), also received this drug for a maximum of 12 doses. Sixteen patients underwent secondary surgery for the removal of residual masses. Twelve (37.5%) entered complete remission (CR) with chemotherapy alone, and an additional 9 cases (28%) were rendered tumor-free by surgery. The 21 disease-free patients (65.5%) received 2 further inductions and no maintenance. Toxicity was moderate, and 1 of the 16 patients who underwent surgery died postoperatively of pulmonary embolism. After a median follow-up period of 26 months (range, 9-60), 2 patients have died in CR and 15 (47%) are currently alive and have been continuously disease-free. The major determinant of tumor response was prior therapy. Eleven of 14 (78%) patients who were not pretreated with cisplatin achieved a continuous disease-free status versus only 4 of the 18 pretreated patients (22%, P <0.01). In this set of cases, complete responders to prior PVB therapy did better than incomplete responders treated for tumor progression. It can be concluded that normal-dose PE ± B therapy, followed by surgical resection of the residual tumor, is a satisfactory salvage therapy in patients not pretreated with cisplatin and is also active in complete responders to prior PVB therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 2399-2403 |
| Number of pages | 5 |
| Journal | Cancer |
| Volume | 56 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer. / Pizzocaro, G.; Pasi, M.; Salvioni, R.; Zanoni, F.; Milani, A.; Piva, L.
In: Cancer, Vol. 56, No. 10, 1985, p. 2399-2403.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cisplatin and etoposide salvage therapy and resection of the residual tumor in pretreated germ cell testicular cancer
AU - Pizzocaro, G.
AU - Pasi, M.
AU - Salvioni, R.
AU - Zanoni, F.
AU - Milani, A.
AU - Piva, L.
PY - 1985
Y1 - 1985
N2 - Thirty-two consecutive patients with pretreated germinal testis cancer received 3 to 4 inductions of cisplatin and etoposide therapy (PE). Patients not pretreated, or only partially pretreated with bleomycin (B), also received this drug for a maximum of 12 doses. Sixteen patients underwent secondary surgery for the removal of residual masses. Twelve (37.5%) entered complete remission (CR) with chemotherapy alone, and an additional 9 cases (28%) were rendered tumor-free by surgery. The 21 disease-free patients (65.5%) received 2 further inductions and no maintenance. Toxicity was moderate, and 1 of the 16 patients who underwent surgery died postoperatively of pulmonary embolism. After a median follow-up period of 26 months (range, 9-60), 2 patients have died in CR and 15 (47%) are currently alive and have been continuously disease-free. The major determinant of tumor response was prior therapy. Eleven of 14 (78%) patients who were not pretreated with cisplatin achieved a continuous disease-free status versus only 4 of the 18 pretreated patients (22%, P <0.01). In this set of cases, complete responders to prior PVB therapy did better than incomplete responders treated for tumor progression. It can be concluded that normal-dose PE ± B therapy, followed by surgical resection of the residual tumor, is a satisfactory salvage therapy in patients not pretreated with cisplatin and is also active in complete responders to prior PVB therapy.
AB - Thirty-two consecutive patients with pretreated germinal testis cancer received 3 to 4 inductions of cisplatin and etoposide therapy (PE). Patients not pretreated, or only partially pretreated with bleomycin (B), also received this drug for a maximum of 12 doses. Sixteen patients underwent secondary surgery for the removal of residual masses. Twelve (37.5%) entered complete remission (CR) with chemotherapy alone, and an additional 9 cases (28%) were rendered tumor-free by surgery. The 21 disease-free patients (65.5%) received 2 further inductions and no maintenance. Toxicity was moderate, and 1 of the 16 patients who underwent surgery died postoperatively of pulmonary embolism. After a median follow-up period of 26 months (range, 9-60), 2 patients have died in CR and 15 (47%) are currently alive and have been continuously disease-free. The major determinant of tumor response was prior therapy. Eleven of 14 (78%) patients who were not pretreated with cisplatin achieved a continuous disease-free status versus only 4 of the 18 pretreated patients (22%, P <0.01). In this set of cases, complete responders to prior PVB therapy did better than incomplete responders treated for tumor progression. It can be concluded that normal-dose PE ± B therapy, followed by surgical resection of the residual tumor, is a satisfactory salvage therapy in patients not pretreated with cisplatin and is also active in complete responders to prior PVB therapy.
UR - http://www.scopus.com/inward/record.url?scp=0022349842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022349842&partnerID=8YFLogxK
U2 - 10.1002/1097-0142(19851115)56:10<2399::AID-CNCR2820561010>3.0.CO;2-V
DO - 10.1002/1097-0142(19851115)56:10<2399::AID-CNCR2820561010>3.0.CO;2-V
M3 - Article
C2 - 2412681
AN - SCOPUS:0022349842
VL - 56
SP - 2399
EP - 2403
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 10
ER -